经颅磁刺激对脑梗死后认知障碍的疗效及C反应蛋白和纤维蛋白原的影响

Clinical Efficacy of TMS in the Cognitive Disorder and Its Impact in the CRP and Fib for Paitents with Cerebral Infarction

目的探讨脑梗死后认知障碍采用经颅磁刺激治疗的疗效。方法整群选取86例于2013年5月—2014年5月期间该院接收的脑梗死后认知障碍患者,随机分为对照组(血栓通注射液,n=43)与实验组(TMS+血栓通注射液,n=43),观察两组治疗疗效及治疗前后实验室指标变化。结果实验组较对照组临床有效率显著要高(P<0.05),分别为76.7%、48.8%;治疗后,实验组ADAS-Cog评分显著降低,Mo CA评分显著升高,分别为(34.52±3.51)分、(23.18±3.45)分,与对照组治疗后(37.85±3.14)分、(20.42±3.52)分比较差异有统计学意义(P<0.05);治疗后,两组CRP、Fib均显著下降,而实验组下降幅度更为显著(P<0.05),分别为(3.07±0.63)g/L、(6.65±2.71)mg/L,对照组分别为(3.74±0.81)g/L、(8.12±2.25)mg/L。结论脑梗死后认知障碍采用经颅磁刺激治疗,可取得显著疗效,降低血浆CRP、Fib水平,具有推广价值。

Objective To analyze the clinical efficacy of TMS （transcranial magnetic stimulation） in the cognitive disorder for paitents with cerebral infarction. Methods Group selection 86 cerebral infarction patients complicated with cognitive dis- order treated from May 2013 to May 2014 in our hospital were selected. The subjects were randomly divided into two groups, 43 cases each group. The control group adopted the Xueshuantong injection; on the basis, the test group also adopt- ed TMS; the clinical efficacy and laboratory index for two groups was observed. Results Treatment was significantly in- creased in experimental group compared with the control group, the clinical efficiency was significantly higher （P 〈 0.05） were 76.7% and 48.8%. After treatment, the experimental group of ADAS cog scores were significantly lower scores of Mo- ca, respectively （34.52 ± 3.51）points, （231.8±3.45）points and control group （37.85 ±3.14）points, （20.42±3.52）points have significant difference （P 〈 0.05）. After the treatment, the two groups of CRP and FIB were decreased significantly, while the experimental group decreased significantly （P 〈 0.05）, respectively （307±0.63） g/L, （6.65±2.71） mg/L, and the control group respectively （3.74± 0.81） g/L,（8.12±2.25） mg/L. Conclusion TMS has an obvious effect in cerebral infarction patients complicated with cognitive disorder,-can reduce the level of CRP and Fib. It is worthy of promotion.